CPR launches ligand binding assay service for large molecules

Clinical research company CPR Pharma Services has launched a new laboratory in Adelaide to provide a ligand binding assay service for biomarkers, monoclonal antibodies, biosimilars and biologics in early- and late-phase clinical trials. The services will complement the firm’s existing lab services focused on small molecules in Asia-Pacific.

The Large Molecule Immunochemistry Analytical Service will be run by John Chappell, an expert in ligand binding assay development, validation and implementation in the drug development arena. Chappell is a member of the AAPS committee that is preparing white papers on biosimilar bioanalytical support. He has worked for over 20 years with CROs such as Covance, ClinTrials BioResearch, BAS Analytics, Veeda and ICON.

“John’s appointment with CPR will bring unparalleled expertise in biologic and biosimilar assay development and validation to the Asia-Pacific region,” said the CEO of CPR Pharma, Jason Valentine.

Valentine added that CPR is unique in the region in providing CRO services coupled with the advantage of full GLP bioanalytical services. According to him, monoclonal antibodies, proteins, biologics and biosimilars are the new growth areas in drug development and will progressively occupy a larger share of drugs developed globally.

“CPR has held off on moving into this space until we found the expertise that would do justice to our philosophy to only offer services when we have industry-leading expertise. CPR now has that expertise in John Chappell, who has commenced building a world-class team within our Adelaide laboratory.”

According to Valentine, several of CPR’s existing clients have already expressed interest in the new services.

“The addition of this service to the already successful and expanding bioanalytical service currently offered by CPR will further enhance our appeal to potential clients who are developing large molecule technology and want to take advantage of the benefits of the region,” he said.